|
Volume 16, Issue 4 (July 2014) 16, 555–560; 10.4103/1008-682X.127824
New developments in the treatment of castration resistant prostate cancer
Roxanne Wadia, Daniel P Petrylak
Department of Medicine, Smilow Cancer Center, Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, Connecticut, USA
Correspondence: Dr. DP Petrylak (daniel.petrylak@yale.edu)
Received: 16 December 2013; Accepted: 12 February 2014 Open Access Prostate
| Abstract |
|
In the past 5 years, the treatment and understanding of metastatic castrate resistant prostate cancer (CRPC) have improved dramatically. Our understanding of the mechanisms of castration resistance has allowed for the development of new drugs to target prostate cancer, and our understanding of genetic mutations may give us new tools with which to more accurately diagnose and be able to predict the course of this heterogeneous disease. This article summarizes the recent advances in the understanding of the development of CRPC, as well as the new drugs and targets, which have evolved from this basic research.
Keywords: castration resistant prostate cancer; abiraterone; enzalutamide; chemotherapy; docetaxel; cabazitaxel; PSMA antibody
Full Text |
PDF |
中文摘要 |
|
| |
| Browse: 3515 |
|
